Literature DB >> 35861472

Anesthesia care in the interventional neuroradiology suite: an update.

Corina Bello1, Chanannait Paisansathan2, Thomas Riva1,3, Markus M Luedi1, Lukas Andereggen4.   

Abstract

PURPOSE OF REVIEW: The scope of procedures conducted by neurointerventionalists is expanding quickly, with lacking consensus over the best anesthesia modality. Although the procedures involve all age groups, the interventions may be complex and lengthy and may be provided in hospitals currently not yet familiar with the field. Here we review current literature addressing elective outpatient neurointerventional procedures and aim to provide an update on the management of intervention-specific crises, address special patient populations, and provide key learning points for everyday use in the neurointerventional radiology suite. RECENT
FINDINGS: Various studies have compared the use of different anesthesia modalities and preinterventional and postinterventional care. Monitored anesthesia care is generally recommended for elderly patients, whereas children are preferably treated with general anesthesia. Additional local anesthesia is beneficial for procedures, such as percutaneous kyphoplasty and vascular access.
SUMMARY: Combining different anesthetic modalities is a valuable approach in the neurointerventional radiology suite. More interventional and patient population-specific studies are needed to improve evidence-based perioperative management.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35861472     DOI: 10.1097/ACO.0000000000001151

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.733


  1 in total

1.  Reply to "Epidemiologic analysis of 8000 acute vertebral fractures: evolution of treatment and complications at 10-year follow-up": food for thought outside the box.

Authors:  Rebecca Straessle; Corina Bello
Journal:  J Orthop Surg Res       Date:  2022-08-13       Impact factor: 2.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.